Phase I study of daily oral AZD 2171, an inhibitor of the vascular endothelial growth factor receptor (VEGFR), in combination with carboplatin/paclitaxel in patients with advanced non-small cell lung cancer (NSCLC): A study of the NCICCTG. Conferences uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Laurie, SA
  • Arnold, A
  • Gauthier, I
  • Ellis, Peter
  • Goss, G
  • Chen, E
  • Shepherd, F
  • Fisher, B
  • Robertson, J
  • Seymour, L

publication date

  • December 15, 2005